- Aleglitazar, a balanced PPAR alpha/gamma agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
[作者：Foley-Comer, AJ; Young, AM; Russell-Yarde, F; Jordan, P,期刊：Expert opinion on investigational drugs, 页码：3-12 , 文章类型： Article，,卷期：2011年20-1]
- Background: Aleglitazar, a dual PPAR-alpha/gamma agonist, combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. Objective: To investigate the pharmacokinetic effects of co-ad...
- Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity
[作者：Leishman, AJ; Sims, GP; Sleeman, M; Braddock, M,期刊：Expert opinion on investigational drugs, 页码：23-39 , 文章类型： Review，,卷期：2011年20-1]
- Importance of the field: Biological therapeutics targeting TNF-alpha, IL-6, CD20 and CD80/86 is proving to be an important weapon in the clinicians' armory to fight autoimmunity alongside long-standing small molecule the...
- Janus kinase 2 inhibitors in myeloproliferative disorders
[作者：Lucia, E; Recchia, AG; Gentile, M; Bossio, S; Vigna, E; Mazzone, C; Madeo, A; Morabito, L; Gigliotti, V; De Stefano, L; Caruso, N; Servillo, P; Franzese, S; Bisconte, MG; Gentile, C; Morabito, F,期刊：Expert opinion on investigational drugs, 页码：41-59 , 文章类型： Review，,卷期：2011年20-1]
- Importance of the field: JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit i...
- Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer
[作者：Nguewa, PA; Calvo, A; Pullamsetti, SS; Banat, GA; Grimminger, F; Savai, R,期刊：Expert opinion on investigational drugs, 页码：61-74 , 文章类型： Review，,卷期：2011年20-1]
- Importance of the field: The 5-year survival rate in NSCLC remains < 15% in spite of new chemotherapeutic regimens and targeted therapies. Tyrosine kinase inhibitors (TKIs) with antiangiogenic properties show promise as ...
|